Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan

PaperCitations, authors & open-access status

Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1 citations, 2026 year and closed oa status.

1
Citations
2026
Year
closed
OA Status

Related on ScholarIQ

Y. Zhang
Author
HER2/EGFR in Cancer Research
Topic
HER2/EGFR in Cancer Research
Topic
Click Chemistry and Applications
Topic
Ubiquitin and proteasome pathways
Topic
470M+ articles · free account